Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Researchers Restore Neuron Function to Brains Damaged by Huntington’s Disease

May 29, 2012 By AxoGen, Inc.

Researchers from South Korea,
Sweden, and the United States
have collaborated on a project to restore neuron function to parts of the brain
damaged by Huntington’s disease (HD) by successfully transplanting HD-induced
pluripotent stem cells into animal models.

Induced pluripotent stem cells (iPSCs) can be genetically
engineered from human somatic cells such as skin, and can be used to model
numerous human diseases. They may also serve as sources of transplantable cells
that can be used in novel cell therapies. In the latter case, the patient
provides a sample of his or her own skin to the laboratory.

In the current study, experimental animals with damage to a
deep brain structure called the striatum (an experimental model of HD)
exhibited significant behavioral recovery after receiving transplanted iPS
cells. The researchers hope that this approach eventually could be tested in
patients for the treatment of HD.

“The unique features of the iPSC approach means that the
transplanted cells will be genetically identical to the patient and therefore
no medications that dampen the immune system to prevent graft rejection will be
needed,” said Jihwan Song, D.Phil. Associate Professor and Director of
Laboratory of Developmental & Stem Cell Biology at CHA Stem Cell Institute,
CHA University, Seoul, South Korea and co-author of the study.

The study, published online this week in Stem Cells, found
that transplanted iPSCs initially formed neurons producing GABA, the chief
inhibitory neurotransmitter in the mammalian central nervous system, which
plays a critical role in regulating neuronal excitability and acts at
inhibitory synapses in the brain. GABAergic neurons, located in the striatum,
are the cell type most susceptible to degeneration in HD.

Another key point in the study involves the new disease
models for HD presented by this method, allowing researchers to study the
underlying disease process in detail. Being able to control disease development
from such an early stage, using iPS cells, may provide important clues about
the very start of disease development in HD. An animal model that closely
imitates the real conditions of HD also opens up new and improved opportunities
for drug screening.

“Having created a model that mimics HD progression from the
initial stages of the disease provides us with a unique experimental platform
to study Huntington’s disease pathology” said Patrik Brundin, M.D., Ph.D.,
Director of the Center for Neurodegenerative Science at Van Andel Research
Institute (VARI), Head of the Neuronal Survival Unit at Lund University, Sweden,
and co-author of the study.

Huntington’s disease (HD) is a neurodegenerative genetic
disorder that affects muscle coordination and leads to cognitive decline and
psychiatric problems. It typically becomes noticeable in mid-adult life, with
symptoms beginning between 35 and 44 years of age. Life expectancy following
onset of visual symptoms is about 20 years. The worldwide prevalence of HD is
5-10 cases per 100,000 persons. Key to the disease process is the formation of
specific protein aggregates (essentially abnormal clumps) inside some neurons.

Link to the study abstract: “Neuronal Properties, In Vivo
Effects and Pathology of a Huntington’s Disease Patient-Derived Induced
Pluripotent Stem Cells” http://www.ncbi.nlm.nih.gov/pubmed/22628015

Related Articles Read More >

Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech